Loading
Rafael Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by JONAS HOWARD S, was filed 09 Jun 2025.
Rafael Holdings, Inc.: what insiders have been doing
Rafael Holdings, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). From 23 October 2025 to 23 October 2026, the disclosure feed for Rafael Holdings, Inc. logged 14 filings by 6 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Over the last twelve months, not one insider purchase of Rafael Holdings, Inc. stock was filed. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (2,023 companies, median 41 filings), a count of 14 filings is below the norm. The full history, which starts in 2018, counts 5 purchases against 3 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 July 2025), the company reported revenue of 917,000 USD and net income of -30.5 m USD.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
133
Thresholds
n/a
Buy Volume
€25M
5 ops. · all time
Sell Volume
€207,175
3 ops. · all time
Who traded when
BuySaleHoward S. Jonas3 buys
Since the insiders bought
- -37.5%Entry US$2.85 · Close at T+365 US$1.78
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,373 of 26,280 companies
29.6
score / 100
Value10
Quality49
FCF yld-12%
Earn yld-51%
EV/EBITDA·
ROE-38%
Gross mgn76%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2024FY ended July 2024 · cache
US$1.29
Analyst consensus
Income statement
RevenueUS$637k
Gross profitUS$483k76% margin
EBITDA-US$66.8M-10485% margin
Net income-US$34.4M-5401.9% margin
Valuation
P/Book0.9x
Beta0.34
Balance sheet & cash
Market capUS$67.1M
Total debtUS$2.4M
Free Cash Flow-US$8M
Debt / Equity1%
Profitability & ownership
ROE-37.6%
ROA-22.8%
% insiders38.2%
% institutions8.1%
Last declaration on 23 September 2026
Declarations133 total
2,027 shares@ US$2.0250.0056% mcap1.1% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-399248:0
54,945 shares@ US$2.730.15% mcap1.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-26-328798:0
2,318 shares@ US$1.2750.8% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-121225:0
9,826 shares@ US$1.50250.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-26-110026:0
29,528 shares@ US$1.2744.1% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-031749:0
39,370 shares@ US$1.2722.7% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-028834:0
6,562 shares@ US$1.27100.0% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-028831:0
39,370 shares@ US$1.2767.2% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-028833:0
50,000 shares@ US$1.2514.1% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-014138:1
75,000 shares@ US$1.24850.7% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-26-014140:0
4,865 shares@ US$1.24851.6% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-26-014138:0
1,961 shares@ US$1.2850.7% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-330708:0
9,867 shares@ US$1.49750.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-25-321293:0
4,180 shares@ US$1.351.5% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-253316:0
1,284 shares@ US$1.480.5% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-217252:0
1,970 shares@ US$1.490.8% of flowClass B Common Stock, par value $.01 per shareSEC:0001193125-25-210807:0
9,905 shares@ US$1.3450.1% of flowClass B Common Stock, $.01 par value per shareSEC:0001193125-25-205211:0
2,347 shares@ US$1.5951.0% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-089354:0
118,596 shares@ US$2.1081.8% of flowClass B Common Stock, $.01 par value per shareSEC:0000950170-25-087209:0
324,219 shares@ US$1.280.8% of flowClass B Common Stock, $.01 par value per shareSEC:0000950170-25-083855:1
Canonical exit: 3 Sept 2025 (T+90)
12,299,207 shares@ US$1.2828.6% of flowClass B Common Stock, $.01 par value per shareSEC:0000950170-25-083855:2
Canonical exit: 3 Sept 2025 (T+90)
457,031 shares@ US$1.284.4% of flowClass B Common Stock, $.01 par value per shareSEC:0000950170-25-083855:0
Canonical exit: 3 Sept 2025 (T+90)
76,882 shares@ US$1.2826.6% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-079559:0
35,000 shares@ US$1.2855.9% of flowClass B Common Stock, par value $.01 per shareSEC:0000950170-25-078854:0
27,454 sharesClass B Common Stock, par value $.01 per shareSEC:0000950170-25-057934:0
25 of 133 declarations
About Rafael Holdings, Inc.
Rafael Holdings, Inc. (NYSE: RFL) is a United States-listed company trading on the NYSE/NASDAQ market, with a business profile that sits squarely in healthcare and biotech. Headquartered in Newark, New Jersey, the company has evolved from a more asset-holding structure into a development-focused biopharmaceutical platform centered on novel therapeutics, especially oncology and rare-disease opportunities. Its corporate base in Newark anchors the group in the northeastern United States. ([rafaelholdings.com](https://rafaelholdings.com/?utm_source=openai))
The company’s operating model is built around a portfolio of controlled and majority-owned healthcare ventures. In its latest annual report, Rafael Holdings describes itself as a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies developing pharmaceuticals and medical devices. Its lead candidate is Trappsol® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal, progressive genetic disorder. Rafael also holds interests in LipoMedix Pharmaceuticals, Barer Institute, and Cornerstone Pharmaceuticals, and it has recently brought Cyclo Therapeutics into its consolidated portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Rafael is best viewed as a small-cap biotech company whose valuation is driven less by current commercial revenues and more by clinical execution, intellectual property, and capital-market access. Its competitive position depends on advancing specialized programs through development milestones, generating meaningful trial data, and maintaining flexibility to support portfolio companies. This is a high-risk, high-upside profile typical of development-stage biotech issuers, where clinical readouts and regulatory progress can materially re-rate the stock. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/ea0262395-10k_rafael.htm?utm_source=openai))
Recent corporate updates have centered on fiscal 2025 results for the year ended July 31, 2025, where the company reported a smaller net loss than in the prior year, alongside higher R&D spending tied to new consolidated activities. Management also highlighted continued progress on Trappsol® Cyclo™ and the broader transition toward a more integrated biopharmaceutical enterprise. For French-speaking investors, Rafael Holdings should be monitored as a speculative U.S. healthcare name on the NYSE, with key catalysts coming from clinical updates, SEC Form 4 insider filings, financing actions, and portfolio-level transactions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103509/ea026292601ex99-1_rafael.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
